COVID-19 stalling Chinese venture financings

A steep downturn in venture rounds raised by Chinese biotechs could be a sign that the ongoing coronavirus crisis will have lasting effects on the growth of the country’s biopharma industry.

Only seven Chinese companies have closed venture rounds so far in 2020, about half as many as in January and February of each of the past two years. ...